keyword
MENU ▼
Read by QxMD icon Read
search

trimetazidin

keyword
https://www.readbyqxmd.com/read/29892472/pharmacological-interventions-effective-in-improving-exercise-capacity-in-heart-failure
#1
REVIEW
Cristiana Vitale, Spoletini Ilaria, Giuseppe Mc Rosano
Heart failure (HF) is characterised by exercise intolerance, which substantially impairs quality of life (QOL) and prognosis. The aim of this review is to summarise the state of the art on pharmacological interventions that are able to improve exercise capacity in HF. Ivabradine, trimetazidine and intravenous iron are the only drugs included in the European Society of Cardiology HF guidelines that have consistently been shown to positively affect functional capacity in HF. The beneficial effects on HF symptoms, physical performance and QOL using these pharmacological approaches are described...
May 2018: Cardiac Failure Review
https://www.readbyqxmd.com/read/29888611/trimetazidine-in-the-prevention-of-tissue-ischemic-conditions
#2
Manolis S Kallistratos, Leonidas E Poulimenos, Sofia Giannitsi, Pavlos Tsinivizov, Athanasios J Manolis
Trimetazidine (TMZ) is a metabolic agent with significant anti-ischemic properties. By inhibiting the terminal enzyme in the β-oxidation pathway, it shifts the energy substrate metabolism, enhancing glucose metabolism. Thus, it maintains the required energy production with less oxygen consumption, an effect necessary in cases of myocardi. Trimetazidine was recently reaccredited as add-on therapy for symptomatic treatment in patients with stable angina, not adequately controlled or intolerant to first-line therapy...
January 1, 2018: Angiology
https://www.readbyqxmd.com/read/29882509/evaluation-of-medication-dosing-errors-in-elderly-patients-with-renal-impairment
#3
Hyo-Joong Won, Gokyung Chung, Kyeong Ju Lee, Eunkyung Lee, Soonjoo Son, Soyoung Choi, Seon Cheol Park, Yu Jeung Lee
OBJECTIVE: The administration of the usual dosage of medication in elderly patients with renal impairment can cause adverse drug reactions due to patients' decreased renal function. Using retrospective prescription analysis, in a teaching hospital, this study aimed to evaluate medication dosing errors in elderly patients with renal impairment and the risk factors for these dosing errors. MATERIALS AND METHODS: This retrospective study included elderly patients with a creatinine clearance of 59 mL/min or less who were hospitalized in a teaching hospital between July 1, 2015, and September 30, 2015...
June 8, 2018: International Journal of Clinical Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/29874661/treatment-of-angina-where-are-we
#4
Cristina Balla, Rita Pavasini, Roberto Ferrari
Ischaemic heart disease is a major cause of death and disability worldwide, while angina represents its most common symptom. It is estimated that approximately 9 million patients in the USA suffer from angina and its treatment is challenging, thus the strategy to improve the management of chronic stable angina is a priority. Angina might be the result of different pathologies, ranging from the "classical" obstruction of a large coronary artery to alteration of the microcirculation or coronary artery spasm...
June 6, 2018: Cardiology
https://www.readbyqxmd.com/read/29779201/clinical-acceptability-of-trimetazidine-modified-release-80-mg-once-daily-versus-trimetazidine-modified-release-35-mg-twice-daily-in-stable-angina-pectoris
#5
Yuri M Pozdnyakov
INTRODUCTION: Trimetazidine (TMZ) is an anti-ischemic metabolic agent that has been shown to be efficacious in angina treatment, both in monotherapy and in combination. A new formulation of TMZ modified-release (MR) 80 mg was developed, which is to be taken once daily (od), instead of twice daily (bid) for the currently available TMZ MR 35 mg, with the aim of simplifying the medication regimen. METHODS: The present study was an international, multicenter, randomized, double-blind, parallel-group phase III study with a 12-week treatment period...
May 19, 2018: Cardiology and Therapy
https://www.readbyqxmd.com/read/29777783/accelerated-lipid-catabolism-and-autophagy-are-cancer-survival-mechanisms-under-inhibited-glutaminolysis
#6
Anna Halama, Michal Kulinski, Shaima S Dib, Shaza B Zaghlool, Kodappully S Siveen, Ahmad Iskandarani, Jonas Zierer, Kirti S Prabhu, Noothan J Satheesh, Aditya M Bhagwat, Shahab Uddin, Gabi Kastenmüller, Olivier Elemento, Steven S Gross, Karsten Suhre
Suppressing glutaminolysis does not always induce cancer cell death in glutamine dependent tumors because cells may switch to alternative energy sources. To reveal compensatory metabolic pathways, we investigated the metabolome-wide cellular response to inhibited glutaminolysis in cancer cells. Glutaminolysis inhibition with C.968 suppressed cell proliferation but was insufficient to induce cancer cell death. We found that lipid catabolism was activated as a compensation for glutaminolysis inhibition. Accelerated lipid catabolism, together with oxidative stress induced by glutaminolysis inhibition, triggered autophagy...
May 16, 2018: Cancer Letters
https://www.readbyqxmd.com/read/29776437/coenzyme-q10-combined-with-trimetazidine-in-the-prevention-of-contrast-induced-nephropathy-in-patients-with-coronary-heart-disease-complicated-with-renal-dysfunction-undergoing-elective-cardiac-catheterization-a-randomized-control-study-and-in-vivo-study
#7
Fei Chen, Fan Liu, Jingchao Lu, Xiuchun Yang, Bing Xiao, Yaqiong Jin, Jie Zhang
BACKGROUND: Contrast-induced nephropathy (CIN) is one of the common hospital-acquired acute renal failures. The purpose of this study was to investigate whether Coenzyme Q10 (CoQ10) and trimetazidine (TMZ) can prevent the occurrence of CIN after elective cardiac catheterization in patients with coronary artery disease complicated with renal dysfunction. METHODS: Consecutive coronary artery disease patients with renal insufficiency scheduled for coronary angiography were enrolled in randomized, paralleled, double-blind, controlled trial...
May 18, 2018: European Journal of Medical Research
https://www.readbyqxmd.com/read/29766461/the-effectiveness-of-trimetazidine-treatment-in-patients-with-stable-angina-pectoris-of-various-durations-results-from-the-choice-2-study
#8
Maria Glezer
INTRODUCTION: Trimetazidine (TMZ) has been shown to reduce angina symptoms and to increase exercise capacity in randomized clinical trials, but more extensive data would be useful to assess its effects in real-world clinical practice and in patients with different durations of disease. METHODS: CHOICE-2 was a Russian, multicenter, 6-month, open-label, prospective observational study that assessed the effect of adding TMZ modified release 35 mg bid to antianginal treatment in a real-world setting...
May 15, 2018: Advances in Therapy
https://www.readbyqxmd.com/read/29660909/the-effect-of-trimetazidine-in-reducing-the-ischemia-reperfusion-injury-in-rat-epigastric-skin-flaps
#9
Laura Petrovics, Tibor Nagy, Peter Hardi, Laura Bognar, Gabor Pavlovics, Gyorgy Tizedes, Ildiko Takacs, Gabor Jancso
BACKGROUND: Ischemia-reperfusion injury may lead to insufficient microcirculation and results in partial flap loss during the free flap surgeries. OBJECTIVE: This study aimed to investigate the effect of trimetazidine (TMZ) on oxidative stress, inflammation and histopathological changes, using the epigastric skin flap model in rats. METHODS: 40 male Wistar rats were used, that were divided into four groups. Control group, non-treated ischemic (I/R)-group and two trimetazidine treated groups (preischemically, postischemically) were established...
April 13, 2018: Clinical Hemorheology and Microcirculation
https://www.readbyqxmd.com/read/29588593/beneficial-effects-of-trimetazidine-on-expression-of-serotonin-and-serotonin-transporter-in-rats-with-myocardial-infarction-and-depression
#10
Meiyan Liu, Wanlin Wei, Christopher R Stone, Lijun Zhang, Guoxiang Tian, Jessie N Ding
Background: Trimetazidine is an anti-ischemic drug that can inhibit platelet aggregation and regulate serotonin (5-hydroxytryptamine [5-HT]) release. The purpose of this study was to investigate the therapeutic effects of trimetazidine on 5-HT and serotonin transporter (SERT) expression in experimentally induced myocardial infarction (MI), depression, and MI + depression. Materials and methods: Eighty Sprague Dawley (SD) rats were randomly divided into a trimetazidine group and a saline group of 40 rats each...
2018: Neuropsychiatric Disease and Treatment
https://www.readbyqxmd.com/read/29582403/medications-and-prescribing-patterns-as-factors-associated-with-hospitalizations-from-long-term-care-facilities-a-systematic-review
#11
REVIEW
Kate N Wang, J Simon Bell, Esa Y H Chen, Julia F M Gilmartin-Thomas, Jenni Ilomäki
BACKGROUND: Residents of long-term care facilities (LTCFs) are at high risk of hospitalization. Medications are a potentially modifiable risk factor for hospitalizations. OBJECTIVE: Our objective was to systematically review the association between medications or prescribing patterns and hospitalizations from LTCFs. METHODS: We searched MEDLINE, Embase, Cumulative Index to Nursing and Allied Health Literature (CINAHL) and International Pharmaceutical Abstracts (IPA) from inception to August 2017 for longitudinal studies reporting associations between medications or prescribing patterns and hospitalizations...
May 2018: Drugs & Aging
https://www.readbyqxmd.com/read/29577822/psychocardiological-disorder-and-brain-serotonin-after-comorbid-myocardial-infarction-and-depression-an-experimental-study
#12
Li-Jun Zhang, Mei-Yan Liu, Radhika Rastogi, Jessie N Ding
Objectives We investigated whether trimetazidine pretreatment can regulate central and peripheral serotonin (5-HT) in rats of myocardial infarction (MI) combined with depression. Methods Forty rats were randomly assigned to a sham operation group (n = 10) and a disease model group (n = 30). The sham operation group was pretreated with normal saline for 4 weeks. The disease model group was randomly assigned further into a negative control subgroup, a positive control subgroup, and a treatment subgroup - the groups received saline, sertraline, and trimetazidine pretreatment, respectively, for 4 weeks, then the rats were subjected to MI combined with depression...
March 26, 2018: Neurological Research
https://www.readbyqxmd.com/read/29554292/trimetazidine-is-there-a-role-beyond-angina
#13
Jason M Tarkin, Juan Carlos Kaski
No abstract text is available yet for this article.
April 1, 2018: European Heart Journal. Cardiovascular Pharmacotherapy
https://www.readbyqxmd.com/read/29506311/the-beneficial-effects-of-trimetazidine-on-reperfusion-induced-arrhythmia-in-diabetic-rats
#14
Fatemeh Ramezani-Aliakbari, Mohammad Badavi, Mahin Dianat, Seyed Ali Mard, Akram Ahangarpour
Trimetazidine (TMZ), as an anti-ischemic drug, plays a critical role in protecting against cardiovascular complications induced by diabetes. This study was therefore aimed to evaluate the protective effects of TMZ on reperfusion-induced arrhythmias in the diabetic rats. Male Sprague-Dawley rats (250±20 g) were randomly assigned to four (n=8): control rats (C), alloxan induced diabetic rats (D), diabetic rats treated with TMZ (10 mg/kg, D+T10), diabetic rats treated with TMZ (30 mg/kg, D+T30). TMZ was treated orally once daily for 8 weeks...
March 5, 2018: Experimental and Clinical Endocrinology & Diabetes
https://www.readbyqxmd.com/read/29371959/modulating-the-metabolism-by-trimetazidine-enhances-myoblast-differentiation-and-promotes-myogenesis-in-cachectic-tumor-bearing-c26-mice
#15
Lucia Gatta, Laura Vitiello, Stefania Gorini, Sergio Chiandotto, Paola Costelli, Anna Maria Giammarioli, Walter Malorni, Giuseppe Rosano, Elisabetta Ferraro
Trimetazidine (TMZ) is a metabolic reprogramming agent able to partially inhibit mitochondrial free fatty acid β-oxidation while enhancing glucose oxidation. Here we have found that the metabolic shift driven by TMZ enhances the myogenic potential of skeletal muscle progenitor cells leading to MyoD, Myogenin, Desmin and the slow isoforms of troponin C and I over-expression. Moreover, similarly to exercise, TMZ stimulates the phosphorylation of the AMP-activated protein kinase (AMPK) and up-regulates the peroxisome proliferator-activated receptor gamma coactivator 1-α (PGC1α), both of which are known to enhance the mitochondrial biogenesis necessary for myoblast differentiation...
December 26, 2017: Oncotarget
https://www.readbyqxmd.com/read/29325311/-effects-of-trimetazidine-a-myocardial-metabolism-agent-on-regulating-5-hydroxytrytamine-system-of-rats-with-myocardial-infarction-and-or-depression
#16
(no author information available yet)
Objective: 5-Hydroxytrytamine (5-HT) system was reported to be associated with myocardial infarction (MI) and depression. The aim of the present study was to study the effect of trimetazidine on 5-HT in MI and/or depression rats. Methods: Ninety rats were divided into three groups: trimetazidine, sertraline and saline groups ( n= 30 in each group), and pretreated with trimetazidine, sertarline, or saline, respectively, by gavage once a day for 4 weeks. Thereafter, each group was further divided into three subgroups: MI subgroup, depression subgroup, and MI+ depression subgroup...
January 1, 2018: Zhonghua Nei Ke za Zhi [Chinese Journal of Internal Medicine]
https://www.readbyqxmd.com/read/29285227/effects-of-trimetazidine-on-periprocedural-microrna-21-expression-by-cd4-t-lymphocytes-in-patients-with-unstable-angina-pectoris
#17
Qiang Su, Lang Li, Jinmin Zhao, Yuhan Sun, Huafeng Yang
Objective: Post-percutaneous coronary intervention (PCI) myocardial injury is related to the CD4+ T lymphocyte-mediated inflammatory response. microRNA-21 expression is associated with CD4+ T lymphocyte activation. The pre-PCI use of trimetazidine prevents periprocedural myocardial injury and reduces inflammatory cytokine levels. This study aimed to assess the effects of trimetazidine on periprocedural microRNA-21 expression by CD4+ T lymphocytes in patients with unstable angina pectoris...
December 1, 2017: Oncotarget
https://www.readbyqxmd.com/read/29152896/trimetazidine-restores-the-positive-adaptation-to-exercise-training-by-mitigating-statin-induced-skeletal-muscle-injury
#18
Ming Song, Fang-Fang Chen, Yi-Hui Li, Lei Zhang, Feng Wang, Ran-Ran Qin, Zhi-Hao Wang, Ming Zhong, Meng-Xiong Tang, Wei Zhang, Lu Han
BACKGROUND: Exercise rehabilitation is demonstrated to improve the prognosis of patients with coronary heart disease (CHD). Statins, as the key medicine to lower cholesterol in CHD, result in skeletal muscle injury and impair exercise training adaptation. Energy metabolism dysfunction is identified as the potential mechanism underlying statin-induced skeletal muscle injury. In this study, we investigated the effects of the metabolic modulator trimetazidine on skeletal muscle energy metabolism and statin-associated exercise intolerance...
February 2018: Journal of Cachexia, Sarcopenia and Muscle
https://www.readbyqxmd.com/read/29148291/effectiveness-and-safety-of-anti-ischemic-trimetazidine-in-patients-with-stable-angina-pectoris-and-type-2-diabetes
#19
Zsófia Meiszterics, Attila Kónyi, Gábor Hild, Zsolt Sárszegi, Balázs Gaszner
Aim & methods: This 6-month prospective, observational, noninterventional, open-label clinical study assessed the effectiveness/safety of trimetazidine in 737 patients with stable angina pectoris and Type 2 diabetes mellitus (OGYI/51534-1/2014). RESULTS: Trimetazidine-based therapy was effective in stable coronary artery disease, with significant improvements from baseline (p < 0.05) in: number of angina attacks/week (2.9 ± 2.4 vs 1.1 ± 1.6), angina severity (Canadian Cardiovascular Society Classification 1...
November 2017: Journal of Comparative Effectiveness Research
https://www.readbyqxmd.com/read/29143297/impact-of-trimetazidine-treatment-on-5-year-clinical-outcomes-in-patients-with-significant-coronary-artery-spasm-a-propensity-score-matching-study
#20
Yong Hoon Kim, Ae-Young Her, Seung-Woon Rha, Byoung Geol Choi, Se Yeon Choi, Jae Kyeong Byun, Ahmed Mashaly, Yoonjee Park, Won Young Jang, Woohyeun Kim, Jah Yeon Choi, Eun Jin Park, Jin Oh Na, Cheol Ung Choi, Hong Euy Lim, Eung Ju Kim, Chang Gyu Park, Hong Seog Seo, Dong Joo Oh
OBJECTIVE: We aimed to evaluate the additive benefit of trimetazidine with well-known antispasmodic agents such as calcium channel blockers and nitrate in patients with significant coronary artery spasm (CAS) as assessed by acetylcholine provocation test up to 5 years. METHODS: A total 1727 patients with significant CAS were enrolled. They were divided into two groups: a trimetazidine group (trimetazidine, diltiazem, and nitrate, n = 695), and control group (diltiazem and nitrate, n = 473)...
April 2018: American Journal of Cardiovascular Drugs: Drugs, Devices, and Other Interventions
keyword
keyword
46422
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"